Electromedical & Electrotherapeutic ApparatusIFRS · EUR

Masimo Corp

Masimo Corp develops and markets noninvasive patient monitoring technologies, hospital automation and connectivity solutions, and remote monitoring devices for healthcare settings. The company sells through direct sales, distributors, and OEM partners, with products used to measure patient status in hospitals, EMS, home care, physician offices, veterinary, and long-term care settings.

Revenue1,527m EUR
+0.0 %y/y
Operating profit (EBIT)310m EUR
+0.0 %y/y
EBIT margin20.3%
+0.0 ppy/y
Net income-152m EUR
+0.0 %y/y
Free cash flow198m EUR
+0.0 %y/y

Fiscal year 2026 · change from previous year

Development 2021–2026

05001,0001,5002,0002,500m EUR2021: 1,144 m EUR2021: EBIT 256 m EUR20212022: 2,036 m EUR2022: EBIT 210 m EUR20222023: 2,048 m EUR2023: EBIT 137 m EUR20232024: 2,094 m EUR2024: EBIT 63 m EUR20242025: 1,527 m EUR2025: EBIT 310 m EUR20252026: 1,527 m EUR2026: EBIT 310 m EUR20261,527310
RevenueOperating profit (EBIT)

Business

Share of revenue
Patient monitoring systems45 %

Core hospital and clinical monitoring platforms used to track patient status noninvasively.

Sensors and consumables30 %

Single-patient-use and reusable sensors and related consumables used with monitoring devices.

Hospital automation and connectivity10 %

Workflow, connectivity, and integration solutions for hospital environments.

Remote monitoring and home care8 %

Devices and solutions used outside acute care, including home care and long-term care.

OEM and partner channel products7 %

Monitoring technologies sold through OEM partners and distributor relationships.

Customers

Masimo sells primarily to healthcare providers and channel partners that need reliable patient monitoring and workflow tools. Its customer base includes hospitals, EMS providers, home care providers, physician offices, veterinarians, long-term care facilities, OEM partners, and distributors. The company also disclosed concentration in a just-in-time distributor, making channel stability important to revenue continuity.

Hospitals and health systems

Buy monitoring platforms, sensors, and connectivity tools to support bedside care and workflow efficiency.

OEM partners

Integrate Masimo technology into third-party devices and platforms to broaden market access.

Distributors and just-in-time distributors

Purchase and resell products, including tender-driven and international orders, to extend commercial reach.

EMS, home care, and long-term care providers

Buy remote and portable monitoring solutions for non-acute and mobile care settings.

Physician offices and veterinarians

Purchase point-of-care monitoring products for smaller clinical and specialty-use settings.

Strategy

Masimo is focused on innovation in noninvasive monitoring, hospital automation, and remote care while using direct, distributor, and OEM channels to expand reach. Management also emphasizes infrastructure investment, potential acquisitions or strategic investments, and continued legal defense of intellectual property as part of its capital allocation and competitive strategy.

Product innovation in monitoring and remote careMedium term

Differentiated technology supports pricing power, clinical adoption, and long-term customer retention.

Channel expansion through OEMs and distributorsShort term

Broader partner coverage increases market access and helps win large tenders and international accounts.

Infrastructure and capital investmentMedium term

Capacity, systems, and operational infrastructure support growth and product commercialization.

Protect intellectual propertyLong term

IP protection helps defend technology differentiation and supports long-term monetization.

Geography

Masimo is described as a global technology company, and its revenue includes foreign sales denominated in various currencies. The company did not provide a country-by-country revenue table in the excerpts, but it highlighted exposure to foreign exchange movements, international distributors, and trade policy changes affecting sourcing from Mexico, China, and Malaysia.

Risks

Masimo faces customer concentration risk, especially through a just-in-time distributor that represented 10% or more of consolidated revenue, and any disruption could materially reduce sales. The company is also exposed to tariffs, trade policy changes, foreign exchange volatility, and supply-chain dependence on Mexico, China, and Malaysia, all of which can raise costs or disrupt product availability. As a medical technology business, it also faces regulatory, reimbursement, and competitive risks, plus ongoing uncertainty around litigation and IP defense.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Customer concentration through a key distributor1Tariffs and trade policy changes2Regulatory and policy changes in healthcare3IP litigation and defense costs4Foreign exchange volatility5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Customer concentration through a key distributorImpact: HighLikelihood: Medium

    One just-in-time distributor represented 10% or more of consolidated revenue, so loss or disruption would materially reduce sales.

    Exposure: Distributor channel

  2. Tariffs and trade policy changesImpact: HighLikelihood: Medium

    Material components and sub-assemblies are sourced or manufactured outside the U.S., making costs and supply availability sensitive to trade actions.

    ExposureMexicoChinaMalaysia sourcing
  3. Regulatory and policy changes in healthcareImpact: MediumLikelihood: High

    Changes in funding, staffing, trade, or regulatory policy can affect customer purchasing and product commercialization.

    Exposure: U.S. healthcare market

  4. IP litigation and defense costsImpact: MediumLikelihood: Medium

    The company expects continued legal defense of intellectual property, which can be costly and uncertain.

    Exposure: Patent and trademark portfolio

  5. Foreign exchange volatilityImpact: MediumLikelihood: Low

    Foreign sales denominated in various currencies can translate into lower U.S. dollar revenue when exchange rates move unfavorably.

    Exposure: International sales

Accounting

Judgemental items
Revenue recognition timing

Large tender contract renewals and shipment timing can shift revenue between quarters.

Impact: Quarterly comparability and reported growth rates

Inventory valuation

Product mix, tariffs, and supply-chain costs affect inventory carrying values and margins.

Impact: Gross profit and cost of goods sold

Goodwill and intangible assets

Acquisitions and technology assets require impairment testing and judgment on useful lives.

Impact: Non-cash impairment charges and balance sheet values

Discontinued operations

The non-healthcare consumer audio business is reported separately from continuing operations.

Impact: Comparability of revenue, profit, and cash flow trends

Stock-based compensation and tax contingencies

Equity awards and uncertain tax positions can materially affect operating expenses and tax expense.

Impact: SG&A, tax provision, and net income

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026